Vol. 9 No. 1 (2022): January-December 2022

Published: 2022-01-25

Full Issue

Vol. 9, January-December 2022

Point of View

Drugs territorialization in the era of PNRR: perspectives, opportunities and considerations from a panel of experts

Anna Maria Marata, Walter Marrocco, Emanuela Arcangeli, Mattia Battistini, Giuliano Buzzetti, Riccardo Candido, Gianluigi Casadei, Francesco Cattel, Arturo Cavaliere, Agostino Consoli, Giovanni Corrao, Guido Didoni, Mauro Di Gesù, Alberto Giovanzana, Matteo Lenzi, Massimo Medaglia, Marta Meloncelli, Stefano Palcic, Marcello Pani, Francesca Patarnello, Emanuele Pria, Dario Scaduto, Valeria Tozzi, Marco Zibellini, Elisa Crovato

155-158
- PDF (Italian)
- ePub
- html
Value generated by the multiplier effect of investments by the pharmaceutical industry in Italy: proposals to promote competitiveness and attractiveness

Francesca Patarnello, Emiliano Briante, Federico Villa

117-122
- PDF (italian)
- ePub
- html
Drugs price and reimbursement regulation: comparators, endpoints and role of the cost-effectiveness

Claudio Jommi, Giovanni Apolone, Giovanna Scroccaro, Valentina Acciai, Antonio Addis, Andrea Ardizzoni, Renato Bernardini, Alberto Bortolami, Alessia Brigido, Giuliano Buzzetti, Pier Luigi Canonico, Francesca Caprari, Stefano Centanni, Chiara Cernetti, Americo Cicchetti, Giorgio Corsico, Francesco Damele, Filippo De Braud, Sara Manurita, Francesco Saverio Mennini, Irene Olivi, Federica Parretta, Lara Pippo, Stefania Pulimeno, Massimo Riccaboni, Giuseppe Rossi, Cecilia Saleri, Alessandra Sinibaldi, Federico Spandonaro, Cristian Stefenoni, Elena Visentin, Pierluigi Viale, Giuseppina Zapparelli, Patrizia Popoli

99-104
- PDF (Italian)
- ePub
- html
How reliable are ICER’s results published in current pharmacoeconomic literature? The controversial issue of price confidentiality

Pierluigi Russo

31-35
- PDF
- ePub
- html

Original Research Articles

Disability weights for castration-resistant prostate cancer: an empirical investigation

Ludovica Borsoi, Oriana Ciani, Rocco De Vivo, Giorgio Ivan Russo, Marcello Scarcia, Chiara De Fino, Patrizia Beccaglia, Irene Luccarini

146-154
- PDF
- ePub
- html
Cost per responder for methotrexate versus other therapies in patients with moderate-to-severe plaque psoriasis in Italy

Giuseppe Pompilio, Davide Integlia

138-145
- PDF (Italian)
- ePub
- html
Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain

Prof. Dr. Jaime Rodríguez Quintosa, Dr. Cintia Cristina Ago, Dr. Antoni Sicras Mainar, Dr. Renata Villoro, Dr. Inés Pérez-Román

133-137
- PDF
- ePub
- html
Treatment management of patients with systemic lupus erythematosus: a delphi consensus analysis

Gian Domenico Sebastiani, Marta Mosca, Roberto Ravasio, Pietro Brambilla, Paola Raimondo, Andrea Doria

123-132
- PDF (Italian)
- ePub
- html
Economic evaluation of treosulfan in patients undergoing allogeneic haematopoietic stem cell transplantation

Chiara Bini, Martina Paoletti, Andrea Marcellusi, Carlo Tomino, Francesco Saverio Mennini

105-116
- PDF (Italian)
- ePub
- html
Budget Impact analysis of a new system of care in Parkinson’s disease patients

Chiara Bini, Francesco Saverio Mennini, Andrea Marcellusi, Martina Paoletti, Carlo Tomino

91-98
- PDF (EN)
- ePub (EN)
- html (EN)
- PDF (IT)
- ePub (IT)
- html (IT)
Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain

Margarita Majem, Rosa Álvarez, Ana Laura Ortega, Lucía Ruiz de Alda, Rocío Gordo, J Francisco García, Yoana Ivanova-Markova, Almudena González-Domínguez, Raquel Sánchez San Cristóbal, Federico Rojo

82-90
- PDF
- ePub
- html
The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study

Arianna Bertolani, Roberto Ravasio, Paola Raimondo, Claudio Jommi

73-81
- PDF (Italian)
- ePub
- html
Analysis of the evolution of the price of oncology drugs after the loss of their patent and the marketing of generic medicines

José Manuel Martínez-Sesmero, Borja Smith, Julen Madurga

68-72
- PDF
- ePub
- html
Introduction of the telemonitoring device Turbo+ in the management of patients suffering from asthma in Italy: a budget impact analysis

Filippo Rumi, Michele Basile, Americo Cicchetti, Rosario Contiguglia, Antonella Pentassuglia, Alessandro Oliva, Gianenrico Senna, Marco Bonavia, Francesco Scarpelli, Marco Benvenuto

58-67
- PDF (Italian)
- ePub
- html
Cost-utility analysis of ceftolozane/tazobactam vs meropenem in patients with hospital-acquired pneumonia (HABP) or ventilator-associated pneumonia (VABP)

Francesco Saverio Mennini, Martina Paoletti, Chiara Bini, Andrea Marcellusi, Marco Falcone, Massimo Andreoni

45-57
- PDF (Italian)
- ePub
- html
Distribution methods of ostomy and incontinence aids in the Italian healthcare setting: an evaluation questionnaire and social burden of direct distribution

Filippo Rumi, Francesca Orsini, Vincenzo Falabella, Pier Raffaele Spena, Americo Cicchetti

36-44
- PDF (Italian)
- ePub
- html
Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations

Giuseppe Pompilio, Alessandro Morabito, Diego L. Cortinovis, Davide Integlia

22-29
- PDF (Italian)
- ePub
- html
A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain

Néboa Zozaya, Teresa Caballero, Teresa González-Quevedo, Pedro Gamboa Setien, M. Ángeles González, Ramón Jódar, José Luis Poveda-Andrés, Encarna Guillén-Navarro, Agustín Rivero Cuadrado, Álvaro Hidalgo-Vega

14-21
- PDF
- ePub
- html
Use of a maturity model for facilitating the introduction of CAR T-cell therapy—Results of the START CAR-T project

Stefania Bramanti, Matteo Carrabba, Alice Di Rocco, Elena Fabris, Luca Gastaldi, Paolo Locatelli, Maria Chiara Tisi

1-8
- PDF
- ePub
- html

Short Communication

Cost analysis of extended half-life recombinant factor IX products in the treatment of haemophilia B in Italy: an update

Andrea Aiello, Maria E. Mancuso, Serena Leone, Letizia Rossi, Lorenzo Cioni, Cristina Teruzzi

9-13
- PDF
- ePub
- html

Erratum

Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy

30
- PDF
- ePub
- html

Vol. 9 No. 1 (2022): January-December 2022

Full Issue

Point of View

Drugs territorialization in the era of PNRR: perspectives, opportunities and considerations from a panel of experts

Value generated by the multiplier effect of investments by the pharmaceutical industry in Italy: proposals to promote competitiveness and attractiveness

Drugs price and reimbursement regulation: comparators, endpoints and role of the cost-effectiveness

How reliable are ICER’s results published in current pharmacoeconomic literature? The controversial issue of price confidentiality

Original Research Articles

Disability weights for castration-resistant prostate cancer: an empirical investigation

Cost per responder for methotrexate versus other therapies in patients with moderate-to-severe plaque psoriasis in Italy

Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain

Treatment management of patients with systemic lupus erythematosus: a delphi consensus analysis

Economic evaluation of treosulfan in patients undergoing allogeneic haematopoietic stem cell transplantation

Budget Impact analysis of a new system of care in Parkinson’s disease patients

Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain

The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study

Analysis of the evolution of the price of oncology drugs after the loss of their patent and the marketing of generic medicines

Introduction of the telemonitoring device Turbo+ in the management of patients suffering from asthma in Italy: a budget impact analysis

Cost-utility analysis of ceftolozane/tazobactam vs meropenem in patients with hospital-acquired pneumonia (HABP) or ventilator-associated pneumonia (VABP)

Distribution methods of ostomy and incontinence aids in the Italian healthcare setting: an evaluation questionnaire and social burden of direct distribution

Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations

A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain

Use of a maturity model for facilitating the introduction of CAR T-cell therapy—Results of the START CAR-T project

Short Communication

Cost analysis of extended half-life recombinant factor IX products in the treatment of haemophilia B in Italy: an update

Erratum

Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy

Browse

banners150

Vol. 9 No. 1 (2022): January-December 2022

Full Issue

Point of View

Original Research Articles

Short Communication

Erratum

Sign up

Browse

banners150